Key facts
- CrisprBits’s last known valuation is $290K (Jun 2022).
- It has raised $3.3M; the latest was Later Stage VC ($3.0M) in Nov 2025.
- Notable investors include Spectrum Impact, BITS BioCyTiH Foundation, Centre for Cellular And Molecular Platforms, India Pistons, Vj Technologies.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for CrisprBits
- ·The full record, as it builds
Funding rounds
No funding rounds for CrisprBits are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CrisprBits
Operator of a health tech firm intended to address critical healthcare needs. The company leverages gene-editing technology to develop innovative diagnostic tools, advanced cell therapies, and disease models, enabling healthcare professionals to improve patient outcomes, accelerate drug discovery, and advance medical research.
- Sector
- Healthcare
- HQ
- Delhi, India
- Founded
- 2020
- Employees
- 30
- Website
- crisprbits.com/
- Ownership
- Privately Held (backing)
CrisprBits doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CrisprBits shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CrisprBits in its N-PORT filings yet. We sweep new filings monthly.